Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo

doi: 10.1186/s13046-015-0205-y

Figure Lengend Snippet: The effect of ABC294640 on SphK activity, S1P or ceramide content in CRC cells. The relative SphK activity ( a and b ), S1P content ( c ) or ceramide level ( d ) (vs. Control group) with indicated ABC294640 treatment were presented. The effect of S1P (5 μM), C6 ceramide (C6, 5 μM) or SKI-II (5 μM) on ABC294640 (1 μM)-induced HT-29 cell growth inhibition and cell death were tested by MTT assay ( e ) and LDH release assay ( f ), respectively. Mean values ± SD of three independent experiments were reported. Statistical analysis was performed comparing treatment groups with vehicle control group (“C”). *P < 0.05. # P < 0.05 vs. ABC294640 only group ( e and f )

Article Snippet: Cell permeable short-chain C6 ceramide was obtained from Avanti Polar Lipids, Inc. (Alabaster, AL).

Techniques: Activity Assay, Control, Inhibition, MTT Assay, Lactate Dehydrogenase Assay

Journal: British Journal of Pharmacology

Article Title: The ceramide kinase inhibitor NVP-231 inhibits breast and lung cancer cell proliferation by inducing M phase arrest and subsequent cell death

doi: 10.1111/bph.12886

Figure Lengend Snippet: Effect of NVP-231 and NVP-995 on CerK activity in transfected MCF-7 cells. (A) MCF-7 cells that were either left untransfected (white column, −) or transfected with a cDNA of human CerK (hCerK, +) were treated for 2 h with the indicated concentrations of NVP-231 (grey columns) or NVP-995 (black column) in the presence of NBD-C6-ceramide as described in the Methods section. Cells were harvested and taken for lipid extraction. Lipids were separated by TLC and analysed on a fluorescence imaging system. The density of spots corresponding to phosphorylated NBD-ceramide was measured and results expressed as % of CerK activity compared with Wt control cells. Data are means ± SD (n = 4). (B and C) MCF-7 cells were treated for 24 h with the indicated concentrations of NVP-231. Lipids were then extracted and taken for LC-MS/MS to quantify C16-C1P (B) and the various ceramide subspecies (C). Results are expressed as pmol lipids per 106 cells and are means ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 considered statistically significant when compared with the control samples; ###P < 0.001 statistically significant when compared with the hCerK overexpressed untreated samples.

Article Snippet: C 6 -ceramide was from Enzo Life Sciences AG (Lausen, Switzerland).

Techniques: Activity Assay, Transfection, Fluorescence, Imaging, Liquid Chromatography with Mass Spectroscopy

Journal: British Journal of Pharmacology

Article Title: The ceramide kinase inhibitor NVP-231 inhibits breast and lung cancer cell proliferation by inducing M phase arrest and subsequent cell death

doi: 10.1111/bph.12886

Figure Lengend Snippet: Tables of Links

Article Snippet: C 6 -ceramide was from Enzo Life Sciences AG (Lausen, Switzerland).

Techniques: